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T
he prevalence of pediatric chronic kidney disease
(CKD) ranges from 15 to 74.7 cases per 1 million
children.1 Mortality among children who progress to
end-stage kidney disease (ESKD) is 30 to 50 times higher
compared to that in the general population.1,2 Most of
the data on pediatric CKD comes from the developed
world. The North American Pediatric Renal Collabora-
tive Trials (NAPRTCS) data (n ¼ 4133) show a progres-
sion rate from CKD stages II to IV to ESKD of 17% at 1
year and 39% at 3 years, with the median time to ESKD
being 4.5 years.3 The NAPRTCS registry and the Chronic
Kidney Disease in Children (CKiD) study identified
several modifiable (proteinuria, hypertension, anemia,
dyslipidemia) and nonmodifiable (age, primary disease,
stage of CKD) risk factors for progression of CKD in
children.3–6 The Effect of Strict Blood Pressure Control
and Angiotensin Converting Enzyme Inhibition on the
Progression of Chronic Renal Failure in Pediatric Patients
(ESCAPE) trial showed that reduction of blood pressure
in children with CKD to below the 50th centile signifi-
cantly reduced the rate of progression.7
There is scant literature on the etiology, rate of pro-
gression, risk factors for progression, comorbidities, and
outcomes in children with CKD from low- to middle-
income countries (LMIC). Common problems in LMIC
include delay in diagnosis, increased burden of comor-
bidities, poor access to health care, high financial burden
of treatment, and lack of social support.8,9,S1S5 There is
a large knowledge gap regarding the risk factors for CKD
progression under such circumstances.8,S6 Better under-
standing of modifiable risk factors and early in-
terventions to delay progression to ESKD in LMIC is
urgent, as many children are unlikely to gain access to
dialysis or transplantation should their kidneys fail.S7
We conducted a prospective cohort study to determine
the rate of progression of CKD stages II to IV, to identify
the risk factors associated with progression of CKD, and
to assess the impact of CKD on quality of life (QoL) in
children attending a pediatric CKD clinic in India.
RESULTS
The recruitment and follow-up algorithm is shown in
Figure 1. The evaluation at recruitment and follow-up
are depicted in Table 1. Demographic details of the
cohort (n ¼ 78) at recruitment are described in Table 2.
Of the 78 children, 5 were lost to follow-up before their
first visit, 3 (4.1%) were lost to follow-up later, and 5
(6.8%) died. A total of 65 children were followed up
for 2 to 3 years or until they reached an estimated
glomerular filtration rate (eGFR) of <15 ml/min per 1.73
m2. The median GFR, CKD stages, and prevalence of
comorbidities at recruitment are described in Table 2.
A total of 25 children (38%) experienced progression
of CKD within 2 years of follow-up. In all, 12 children
had a >50% decline from baseline glomerular filtration
rate (GFR), 8 reached a GFR of <15 ml/min per 1.73 m2, 4
were initiated on dialysis, and 1 child underwent renal
transplantation.
The median rate of decline in GFR was 3.5 (IQR 1.7,
11.00) ml/yr. The median time to progression of CKD was
22.98 (IQR 20.56, 25.41) months. There was no significant
difference in the time to progression between incident and
the prevalent cases after recruitment into the study, and
therefore further analyses were conducted on pooled data.
Nonmodifiable Risk Factors for Progression at
Baseline
Age at onset of CKD and sex were not associated with
progression. The risk of progression was significantly
greater in children with glomerular compared with
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nonglomerular disease (hazard ratio [HR] 2.59, 95%
confidence interval [CI] 1.07, 6.27, P ¼ 0.034). The
median decline in GFR was 11.36 (IQR 8.7, 12.6) ml/yr,
and the mean time to progression of CKD was 15.45
(IQR 9.64, 21.25) months in children with glomerular
disease compared to 2.38 ml/yr (IQR 1.1, 4.2) and 24.43
months (IQR 20.56, 25.41) in those with nonglomerular
disease (P ¼ 0.007 and P ¼ 0.021 respectively,
Figure 2a). An eGFR of <45 ml/min at recruitment was
associated with a hazard ratio of 3.3 (95% CI 1.3, 8.4)
for progression (P ¼ 0.009).
Modifiable Risk Factors for Progression at
Baseline
Proteinuria was present in 73 children (93%) at recruit-
ment (Table 2). Urine protein-to-creatinine ratio (UPCr) of
>2 at baseline was associated with risk of progression of
CKD (HR 3.1, 95% CI 1.33, 7.23, P ¼ 0.009) (Figure 2b).
Proteinuria was also associated with progression of CKD
in children with nonglomerular disease (HR 1.5, 95% CI
1.21, 1.9, P¼ 0.02). Hypertension was present in 46 of 78
children (59%) at recruitment (Table 2). Hypertension or
systolic/diastolic z scores at recruitment were not associ-
ated with CKD progression. When adjusted for baseline
eGFR, the following parameters were associated with an
increased risk of progression: anemia, hypocalcemia,
hyperphosphatemia, hyperparathyroidism, and height z
score (Table 3).
Risk Factors for Progression on Follow-up
Persistent proteinuria (UPCr > 2) was significantly asso-
ciated with progression of CKD (HR 1.4, 95% CI 1.2, 1.52;
P ¼ 0.005). Children with uncontrolled hypertension on
follow-up had a higher risk of progression (HR 2.53, 95%
CI, 1.01, 6.67) compared to those who had normal blood
pressure values or controlled hypertension (P ¼ 0.04).
Figure 1. Algorithm depicting recruitment and follow-up of the cohort. CKD, chronic kidney disease; ESKD, end-stage kidney disease.
Table 1. Evaluation of the patient at recruitment and follow-up
Evaluation Recruitment 6 mo 1-yr follow-up 18 mo 2-yr follow-up
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eGFR, estimated glomerular filtration rate.
aClinical details and eGFR done 6 monthly.
bInvestigations repeated at yearly intervals.
cMetabolic panel: serum electrolytes, serum bicarbonate.
RESEARCH LETTERS
Kidney International Reports (2019) 4, 1472–1493 1473
Adherence to antihypertensive medications was docu-
mented in 92% of the cohort. The combination of severe
proteinuria on follow-up (UPCr > 2) and uncontrolled
hypertension at last follow-up was associated with a
hazard ratio of 4.2 (95% CI, 1.8, 9.6, P ¼ 0.001) for
progression.
On multivariate analysis, glomerular disease, base-
line GFR <45 ml/min, UPCR >2, and the combination
of uncontrolled hypertension and proteinuria at
follow-up were independent risk factors for progres-
sion of CKD (Table 3).
Impact of Disease on Quality of Life
The median QoL scores of the child (n ¼ 45) and par-
ents (n ¼ 47) are shown in Table 4.
The total scores of the child and the parent corre-
lated significantly (P ¼ 0.01, r ¼ 0.6). The physical and
psychosocial scores were significantly lower in the
children with lower socioeconomic status (P ¼ 0.035,
r ¼ 0.522). There was no difference in the QOL scores
based on etiology or stage of CKD. The parent proxy
physical score correlated significantly with the height z
score (P ¼ 0.002, r ¼ 0.485), eGFR (P ¼ 0.003, r ¼
0.475), and parent proxy psychosocial score (P < 0.001,
r ¼ 0.796). The parent proxy psychosocial score
correlated with the height z score (P ¼ 0.004, r ¼
0.459), eGFR (P ¼ 0.025, r ¼ 0.367) and psychosocial
score of the child (P ¼ 0.001, r ¼ 0.73). The psycho-
social score was also significantly lower in patients
with lower socioeconomic status (P ¼ 0.032).
DISCUSSION
This prospective longitudinal study from a tertiary care
hospital in an LMIC shows that children with CKD pre-
sent late and have a rapid rate of progression. As in most
pediatric CKD studies,S8,S9 hypodysplasia, obstructive
uropathy, and reflux nephropathy together accounted
for about 50% of cases. Glomerular disease and baseline
eGFR were significant nonmodifiable risk factors for
progression of CKD. Proteinuria, uncontrolled hyper-
tension, and the combination of these were significant
modifiable risk factors for progression. Socioeconomic
status, eGFR, and height z scores were significantly
associated with lower QoL scores.
Very little has been reported on outcomes of children
with CKD in LMIC.S6 The median eGFR in our cohort was
lower than that observed in CKiD and the Italkid project,
34.7 versus 44 and 41.7 ml/min per 1.73 m2, respective-
ly.S8,S10 It is of concern that one-third of the patients in our
cohort were newly diagnosed with CKD (stage IIIb) at the
time of recruitment. This reflects the delay in diagnosis of
CKD in our population, which is common in practice in
LMIC. A similar low baseline eGFR of 33 ml/min per 1.73
m2 was reported from Brazil.S11
The rate of progression of CKD in our cohort was
faster than that reported in other studies.4,S12 The
median rate of decline in GFR was 3.5 ml/yr, almost
twice that in the CKiD study (1.8 ml/yr).S12 A compa-
rable rate of decline in GFR of 5.8 ml/yr was reported
from the Latin American Registry.S13 The mean time to
progression of CKD in our cohort was 1.8 years. The
median time to ESKD was 4.5 years in the NAPRTCS
Table 2. Demographic characteristics of the cohort
Demographic characteristics (n [ 78) Number
Age, mo, median (IQR) 108 (69.2, 134.2)
Sex (%) Male, 75%
Duration of CKD from diagnosis, mo,
median (IQR)
12 (321)
Stage of CKD, n (%) Stage II, 21 (27)
Stage III, 26 (33)
(IIIa, 14; IIIb, 12)
Stage IV, 31 (40)
eGFR (ml/min per 1.73 m2) at recruitment,
median (IQR)
34.67 (24.3, 65.4)
Incident cases (n ¼ 28, 36%) 32 (21.5, 55.6)
Prevalent cases 37 (27.2, 68.1)
Prematurity/low birthweight 14 (19)
Educational status of parents 68% Nongraduates






Glomerular disease 12 (15)
Nonglomerular disease
Renal hypoplasia/dysplasia 20 (25.6)
Obstructive uropathy 12 (15.3)
Neurogenic bladder 13 (16.6)
Reflux nephropathy 5 (6.4)
Others 14 (18)
Unknown 2 (2.5)
Comorbidities associated with CKD at recruitment
Proteinuria (n ¼ 73, 93.5%) UPCr >2, 36 (46)
ACEi use, 4 (5)
Hypertension (n ¼ 46, 59%) Treated, 21 (45.6)
Uncontrolled BP, 14 (66)
Anemia n ¼ 29 (37.17)
Mineral bone disease Bony deformities, 14 (19)
Hypocalcemia, 36 (46.1)
Hyperphosphatemia, 25 (32)
Vitamin D deficiency, 72 (92.3)
Hyperparathyroidism, 44 (56.4)
Cardiovascular Dyslipidemia, 50 (64)
LVH, 34 (44.7)
CIMT, cm, mean 0.05  0.008 SD
Growth Median height z score,
2.1 (3.3, 1.16)
Short stature, 51 (65.4)
Median BMI z score, 1 (2, 0.12)
Undernourished, 20 (25.6)
Delayed puberty, 22 (66)
Metabolic acidosis 59 (75.7)
ACEi, angiotensin-converting enzyme inhibitor; BMI, body mass index; BP, blood
pressure; CIMT, carotid intima-media thickness test; CKD, chronic kidney disease; eGFR,
estimated glomerular filtration rate; LVH, left ventricular hypertrophy; IQR, interquartile
range; UPCr, urine protein-to-creatinine ratio.
Numbers in parentheses are percentages unless otherwise noted.
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registry4 and 8.2 years in Brazil.S14 In Japan, 12.5% of
predialysis children with CKD progressed to ESKD in
1.49 years.S15 The higher rate of progression and
shorter time to progression of CKD in our cohort may
be multifactorial, including the fact that our children
were diagnosed at later stages of CKD and may have
received insufficient treatment related to costs and to
health literacy of parents. Variability in time to CKD
Figure 2. (a) The survival analysis showing time to progression of chronic kidney disease (CKD) in children with glomerular disease in com-
parison to those with nonglomerular disease. Children with glomerular disease had a higher risk of progression when compared to those with
nonglomerular disease (hazard ratio 2.59, 95% confidence interval 1.07, 6.27, P ¼ 0.034). (b) Survival analysis comparing time to progression of
CKD among children with proteinuria (urine protein-to-creatinine ratio [UPCr] > 2) and those without proteinuria. UPCr > 2 at baseline was
associated with the risk of progression of CKD (hazard ratio 3.1, 95% confidence interval 1.33, 7.23, P ¼ 0.009).
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progression may also reflect nonuniform definitions
used across studies. The similar progression rate in our
incident and prevalent patients is concerning; howev-
er, time from diagnosis was not known in prevalent
patients, and the numbers may have been too small to
detect a true difference.
The major nonmodifiable risk factors for progression
in our cohort were glomerular disease as the etiology of
CKD and a lower baseline GFR. This is consistent with
findings from the CKiD and other studies,7,8,S12,S14
which reported baseline GFR as a significant risk factor
for progression, and the NAPRTCS 2010, which
showed that primary disease and stage of CKD were
significant risk factors for progression of CKD.3
Proteinuria was present in children with both
glomerular and nonglomerular disease, and the degree
of proteinuria was 4 times higher than that reported in
the CKiD cohort.6,S16 The severity of proteinuria likely
reflects disease severity, delay in diagnosis of CKD, and
lower prevalence of angiotensin-converting enzyme
inhibitor use in our population. Only 5% of our pa-
tients received angiotensin-converting enzyme in-
hibitors compared to 50% in the CKiD study,S16 and
therefore subgroup analysis was not possible. Pro-
teinuria at recruitment and follow-up were significant
predictors of progression on multivariate analysis and
after correction for baseline GFR, as reported by oth-
ers.S14,S15 Proteinuria adjusted for GFR was signifi-
cantly associated with reduced time to reach ESKD in
children with both glomerular and nonglomerular
disease in the CKiD study.5 The Ital-Kid project showed
that children with a P/Cr of <0.9 had a slower decline
of renal function and a better renal survival at 5
years.S10
The prevalence of hypertension in our study was
comparable with that reported in the CKiD cohort.5,S8 In
contrast to the CKiD study, hypertension at recruitment
was not a significant risk factor for progression of CKD
in our study. However, on follow-up, children with
uncontrolled hypertension had a higher risk of pro-
gression of CKD. The ESCAPE trial showed that inten-
sive control of blood pressure was associated with a
reduced risk of progression of CKD, emphasizing the
importance of blood pressure control in pediatric CKD.7
Anemia was found to be a significant predictor of
progression on univariate but not multivariate analysis
in our cohort. In contrast, data from the CKiD study
found that anemia was a significant predictor of pro-
gression in children with nonglomerular disease, as did
the NAPRTCS overall.3,5 Similarly, low calcium, high
phosphate, and hyperparathyroidism were signifi-
cantly associated with progression on univariate but
not multivariate analysis, likely reflecting associations
with severity of renal dysfunction. This is also in
contrast to the NAPRTCS data, which found that
inorganic phosphorus of >5.5 mg/dl and calcium
of <9.5 mg/dl were associated with a higher risk of
progression.3 The lack of significance of these param-
eters in our cohort may reflect the relatively small
participant number.
Quality of life correlated significantly with short
stature, eGFR, and socioeconomic status. The CKiD
study showed that older children and those with a
longer duration of CKD had higher scores in the phys-
ical, social, and emotional domains, but significantly
lower school domain scores.S17 Short stature was
significantly associated with poor scores in the physical
function domain.S18
Our study has important strengths and some limi-
tations. A major strength of this study is its prospective
longitudinal nature, and the study is, to our
Table 3. Univariate analysis and multivariate analysis of baseline




Hazard ratio (95% CI)
after adjusting for
baseline GFR P value
Nonmodifiable risk factors
Glomerular disease 2.59 (1.07, 6.27) 0.034
eGFR at baseline 3.3 (1.3, 8.4) 0.001
Modifiable risk factors 0.56
Proteinuria 3.1 (1.3, 7.2) 0.009
Hypertension 1.4 (0.43, 4.9) 0.56
Anemia 4.08 (1.8, 9.26) 0.001
Calcium level 0.3 (0.19, 0.487) <0.001
Phosphate level 2.09 (1.36, 3.22 0.001
Parathormone level 1.004 (1.002, 1.005) <0.001
Height z score 0.75 (0.6, 0.9) 0.006
Metabolic acidosis 3.05 (0.91, 10.2) 0.071
Multivariate analysis
Glomerular disease 2.7 (1.1, 6.3) 0.032
eGFR at baseline 3.39 (1.3, 8.8) 0.005
Proteinuria (baseline) 1.04 (1.01, 1.07) 0.009
Proteinuria on follow-up 1.4 (1.2, 1.52) 0.005
Uncontrolled hypertension at last follow-upa 2.53 (1.01, 6.77) 0.04
Uncontrolled hypertension at last follow-up þ
proteinuriaa
4.2 (1.85. 9.63) 0.001
CI, confidence interval; eGFR, estimated glomerular filtration rate; GFR, glomerular
filtration rate.
aUncontrolled hypertension is defined as blood pressure above the 95th centile for age
and sex despite medications.
Numbers in bold indicate statistically significant risk factors.
Table 4. Quality of life scores of child and parent proxy in the cohort
of children with chronic kidney disease
Score Child (n [ 45 ) Parent (n [ 47 )
Physical score 76.56 (62.37, 82.81) 75 (42.18, 89.05)
Psychosocial score 71.66 (64.16, 78.74) 75 (55.8, 86.6)
Total score 72.26 (60.17, 82.05) 70.47 (50.6, 83.36)
Data are median (interquartile range).
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knowledge, one of the few studies from an LMIC
setting. Although this is a single-center study with a
relatively small sample, our geographic catchment area
is large and is representative of children with CKD in
our region. Despite not reaching the target sample size,
the pooled analyses revealed highly plausible findings
that reflect the day-to-day reality in our clinic,
including late presentation and loss to follow-up.
Given the small numbers, subgroup analysis of
comorbidities associated with CKD and other factors
such as low birthweight, prematurity, medication use,
and diet could not be analyzed. Owing to resource
limitations, we could not measure albumin-to-
creatinine ratio. However, with a significant associa-
tion between proteinuria and progression, a spot urine
protein-to-creatinine ratio remains a valid and afford-
able target for treatment in our cohort. Better data on
the burden of hypertension using ambulatory blood
pressure measurement would have been helpful;
however, this was not routinely available in our
setting. The significant association with blood pressure
as measured with CKD progression also provides a
reproducible target for intervention.
CONCLUSION
This prospective, longitudinal study shows that the
profile of children with CKD stages II to IV in an LMIC
is different from those in developed countries. The
lower median baseline GFR suggests delay in diagnosis
of CKD. The rate of progression of CKD was high,
particularly in those with glomerular disease and
associated with proteinuria and uncontrolled blood
pressure, suggesting that the risk factors associated
with progression of CKD must be identified early and
treated adequately. The QoL analysis emphasizes the
impact of CKD on affected children and highlights the
role of socioeconomic status, which influences the
ability to seek and to use medical care. There is an
urgent need to increase awareness of pediatric CKD in
LMICs to facilitate early diagnosis and intervention.
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